This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Spencer Trask Applauds Better Care At Lower Cost For Biotech Products

NEW YORK, June 3 /PRNewswire/ -- Spencer Trask congratulates PROLOR Biotech, Inc. (NYSE/AMEX: PBTH) for ringing the NYSE opening bell at 9:29 am EDT today.  PROLOR is a company co-founded and backed by Spencer Trask five years ago, and has recently been listed on the NYSE/AMEX and Tel Aviv stock exchanges.

PROLOR develops long-acting versions of already approved therapeutic proteins.

CTP (carboxyl-terminal peptide) appears to be applicable to virtually all proteins. Initially, PROLOR is developing long-acting versions of human growth hormone, interferon beta, factor VII, factor IX and EPO (erythropoietin). These products currently generate billions of dollars annually.

By extending the efficacy window, CTP reduces the cost and improves compliance for millions of patients reliant upon biotech proteins. The company believes these products, CTP-enhanced protein therapeutics, have the potential to address biopharmaceutical markets estimated at more than $25 billion. Biotech therapy is one of the fastest-growing (and most profitable) segments of the pharmaceutical industry.

William Clifford, CEO of Spencer Trask said "After a year of unprecedented international economic turmoil, we are pleased to share such a great success with our network of investors, including the visionary leader of TEVA, the largest generic drug company. Spencer Trask is committed to missions like this with large-scale impact. PROLOR Biotech is a shining example of how we network to create important companies."

About Spencer Trask

Spencer Trask develops innovative ideas into world-changing companies.  The company is the legacy of Mr. Spencer Trask, the financier who backed Thomas Edison and invested in the light bulb, the first electric grid and the phonograph. Modern day Spencer Trask has the same entrepreneurial spirit, recognizing new ideas that are having a profound impact in their respective industries, such as: Myriad Genetics; Ciena; Osiris Therapeutics; Health Dialog and InnoCentive.

For more on Spencer Trask, visit

For more on PROLOR, visit


A registered representative of Spencer Trask serves on the Board of PROLOR Biotech Inc. Spencer Trask Ventures has in the past and may in the future provide financial advisory services to PROLOR. Affiliates of Spencer Trask own equity positions in PROLOR Biotech Inc.

SOURCE Spencer Trask

Copyright 2009 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
PBTH $8.23 0.00%
AAPL $95.18 1.64%
FB $117.44 -0.95%
GOOG $692.33 -0.84%
TSLA $232.32 -3.92%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs